Fig. 6: The combination of hederagenin and cisplatin inhibits tumor growth in an NCI-H1299 mouse xenograft model. | Cell Death & Disease

Fig. 6: The combination of hederagenin and cisplatin inhibits tumor growth in an NCI-H1299 mouse xenograft model.

From: Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells

Fig. 6

a Xenograft tumors were induced in nude mice by subcutaneous injection of NCI-H1299 cells in the right flank. When the tumor volume reached 0.1 mm3, the mice were divided into four groups (n = 8 for each group) and treated by hederagenin (25 mg/kg) or cisplatin (1 mg/kg) or a combination of hederagenin and cisplatin. b The tumors were resected and weighed on the 11th day of drug treatment; data was visualized by GraphPad software. Error bars represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Q value > 1.15 indicted a synergistic effect. c Tumor volume was measured and recorded every day and was lower in the combination-treated groups than in the cisplatin group. Data are presented as mean ± standard error. ***p < 0.001, Cis group vs. Hed+Cis group. Q value > 1.15 indicted a synergistic effect. Hederagenin, Hed; cisplatin, Cis.

Back to article page